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S

ince the original publication (in 1995) of the American Heart
Association (AHA) consensus statement on secondary prevention, which was endorsed by the American College of
Cardiology (ACC), important evidence from clinical trials has
emerged that further supports the merits of aggressive risk
reduction therapies for patients with atherosclerotic cardiovascular disease. As noted in that statement, aggressive risk factor
management clearly improves patient survival, reduces recurrent
events and the need for interventional procedures, and improves
the quality of life for these patients.
The compelling evidence from recent clinical trials was the
impetus to revise the 1995 guidelines (Table). As examples,
the many lipid reduction trials have generated significant
changes in the National Heart, Lung, and Blood Institute’s
Adult Treatment Panel III report. This report further defined
target cholesterol levels, expanded indications for drug treatment, and initiated therapy earlier. Accumulating ␤-blocker
data have resulted in broader indications for a larger patient
group. The Heart Outcomes Prevention Evaluation (HOPE)
trial has demonstrated the benefit of ACE inhibitor therapy in
high-risk patients with cardiovascular disease without a
history of an acute event. Further data from ongoing trials
should provide insight into the potential benefits of treating
lower risk patients with combined therapies. The Clopidogrel
versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial has provided evidence for clopidogrel benefit in
certain patients. Diabetes management recommendations
have been updated to include recent guidelines from the

American Diabetes Association for risk factor management
of diabetics and the growing body of evidence showing
diabetics at high risk for cardiovascular events. The Heart and
Estrogen/progestin Replacement Study (HERS) documented
that hormone replacement therapy is ineffective for secondary prevention. The writing group revising this document also
considered other important trials and reports, and they are
included in the selected reading list.
In the 6 years since the guidelines were first published, 2
other developments have made them even more important in
clinical care: the aging of the population continues to expand
the number of patients living with a diagnosis of cardiovascular disease (now estimated at 12.4 million), and the
multiple studies of the actual use of these recommended
therapies in appropriate patients, while showing slow improvement, have continued to support the discouraging conclusion that a large proportion of patients in whom therapies
are indicated are not receiving those therapies in actual
clinical practice. The AHA and ACC continue to urge that all
medical care settings in which these patients are managed
organize a specific plan to identify appropriate patients,
provide practitioners with useful reminder clues based on the
guidelines, and continuously assess the success achieved in
providing all appropriate therapies to all of the patients who
can benefit from them.

Selected Reading
1. Adult Treatment Panel III. Executive summary of the third report of the
National Cholesterol Education Program (NCEP) Expert Panel on
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Intervention Recommendations

Smoking:
Goal
complete cessation

Assess tobacco use. Strongly encourage patient and family to stop smoking and to avoid secondhand smoke. Provide
counseling, pharmacological therapy, including nicotine replacement and buproprion, and formal smoking cessation
programs as appropriate.

BP control:
Goal
⬍140/90 mm Hg or
⬍130/85 mm Hg if
heart failure or renal
insufficiency
⬍130/80 mm Hg if
diabetes

Initiate lifestyle modification (weight control, physical activity, alcohol moderation, moderate sodium restriction, and
emphasis on fruits, vegetables, and low-fat dairy products) in all patients with blood pressure ⱖ130 mm Hg systolic or
80 mm Hg diastolic.
Add blood pressure medication, individualized to other patient requirements and characteristics (ie, age, race, need for
drugs with specific benefits) if blood pressure is not ⬍140 mm Hg systolic or 90 mm Hg diastolic or if blood pressure is
not ⬍130 mm Hg systolic or 85 mm Hg diastolic for individuals with heart failure or renal insufficiency (⬍80 mm Hg
diastolic for individuals with diabetes).

Lipid management:
Primary goal
LDL ⬍100 mg/dL

Start dietary therapy in all patients (⬍7% saturated fat and ⬍200 mg/d cholesterol) and promote physical activity and
weight management. Encourage increased consumption of omega-3 fatty acids. Assess fasting lipid profile in all patients,
and within 24 hr of hospitalization for those with an acute event. If patients are hospitalized, consider adding drug
therapy on discharge. Add drug therapy according to the following guide:
LDL ⬍100 mg/dL
(baseline or on-treatment)
Further LDL-lowering therapy not
required
Consider fibrate or niacin (if low
HDL or high TG)

LDL 100–129 mg/dL
(baseline or on-treatment)
Therapeutic options:
Intensify LDL-lowering therapy
(statin or resin*)
Fibrate or niacin (if low HDL or
high TG)
Consider combined drug therapy
(statin⫹fibrate or niacin) (if low
HDL or high TG)

LDL ⱖ130 mg/dL
(baseline or on-treatment)
Intensify LDL-lowering therapy
(statin or resin*)
Add or increase drug therapy
with lifestyle therapies

Lipid management:
Secondary goal
If TG ⱖ200 mg/dL,
then non-HDL† should
be ⬍130 mg/dL

If TG ⱖ150 mg/dL or HDL ⬍40 mg/dL: Emphasize weight management and physical activity. Advise smoking cessation.
If TG 200–499 mg/dL: Consider fibrate or niacin after LDL-lowering therapy*
If TG ⱖ500 mg/dL: Consider fibrate or niacin before LDL-lowering therapy*
Consider omega-3 fatty acids as adjunct for high TG

Physical activity:
Minimum goal
30 minutes 3 to 4 days
per week
Optimal daily

Assess risk, preferably with exercise test, to guide prescription.
Encourage minimum of 30 to 60 minutes of activity, preferably daily, or at least 3 or 4 times weekly (walking, jogging,
cycling, or other aerobic activity) supplemented by an increase in daily lifestyle activities (eg, walking breaks at work,
gardening, household work). Advise medically supervised programs for moderate- to high-risk patients.

Weight management:
Goal
BMI 18.5–24.9 kg/m2

Calculate BMI and measure waist circumference as part of evaluation. Monitor response of BMI and waist circumference
to therapy.
Start weight management and physical activity as appropriate. Desirable BMI range is 18.5–24.9 kg/m2.
When BMI ⱖ25 kg/m2, goal for waist circumference is ⱕ40 inches in men and ⱕ35 inches in women.

Diabetes management:
Goal
HbA1c ⬍7%

Appropriate hypoglycemic therapy to achieve near-normal fasting plasma glucose, as indicated by HbA1c.
Treatment of other risks (eg, physical activity, weight management, blood pressure, and cholesterol management).

Antiplatelet agents/
anticoagulants:

Start and continue indefinitely aspirin 75 to 325 mg/d if not contraindicated. Consider clopidogrel 75 mg/d or warfarin if
aspirin contraindicated. Manage warfarin to international normalized ratio⫽2.0 to 3.0 in post-MI patients when clinically
indicated or for those not able to take aspirin or clopidogrel.

ACE inhibitors:

Treat all patients indefinitely post MI; start early in stable high-risk patients (anterior MI, previous MI, Killip class II [S3
gallop, rales, radiographic CHF]). Consider chronic therapy for all other patients with coronary or other vascular disease
unless contraindicated.

␤-Blockers:

Start in all post-MI and acute ischemic syndrome patients. Continue indefinitely. Observe usual contraindications. Use as
needed to manage angina, rhythm, or blood pressure in all other patients.

BP indicates blood pressure; TG, triglycerides; BMI, body mass index; HbA1c, major fraction of adult hemoglobin; MI, myocardial infarction; and CHF, congestive
heart failure.
*The use of resin is relatively contraindicated when TG ⬎200 mg/dL.
†Non-HDL cholesterol⫽total cholesterol minus HDL cholesterol.

Downloaded from http://circ.ahajournals.org/ at University of South Carolina--Columbia on June 11, 2013

Smith et al
detection, evaluation, and treatment of high blood cholesterol in adults.
JAMA. 2001;285:2486 –2497.
2. American Diabetes Association clinical practice recommendations 2001.
Diabetes Care. 2001;24(suppl 1):s33–s43.
3. Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular
disease by prolonged antiplatelet treatment. Br Med J (Clin Res Ed).
1988;296:320 –331.
4. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial
infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106.
5. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for
the management of patients with unstable angina and non–ST-segment
elevation myocardial infarction: a report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines (Committee on Management of Acute Myocardial Infarction).
Circulation. 2000;102:1193–1209.
6. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel
versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet.
1996;348:1329 –1339.
7. Cairns JA, Markham BA. Economics and efficacy in choosing oral
anticoagulants or aspirin after myocardial infarction. JAMA. 1995;273:
965–967.
8. DeBusk RF, Miller NH, Superko HR, et al. A case-management system
for coronary risk factor modification after acute myocardial infarction.
Ann Intern Med. 1994;120:721–729.
9. Fletcher GF, Balady GJ, Amsterdam E, et al. Exercise standards for
testing and training: a statement for healthcare professionals from the
American Heart Association. Circulation. In press.
10. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of
coronary heart disease by implementation of a cardiac hospitalization
atherosclerosis management program (CHAMP). Am J Cardiol. 2001;
87:819 – 822.
11. Gibbons RJ, Chatterjee K, Daley J, et al, and the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines (Committee on Management of Acute Myocardial
Infarction). Guidelines for the management of patients with chronic
stable angina. Circulation. 1999;99:2828 –2848.
12. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes mellitus: a major
risk factor for cardiovascular disease: a joint editorial by the American
Diabetes Association, the National Heart, Lung, and Blood Institute, the
Juvenile Diabetes Foundation International, the National Institute of
Diabetes and Digestive and Kidney Diseases, and the American Heart
Association. Circulation. 1999;100:1132–1133.
13. Hambrecht R, Niebauer J, Marburger C, et al. Various intensities of
leisure time physical activity in patients with coronary artery disease:
effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions. J Am Coll Cardiol. 1993;22:468 – 477.
14. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting
enzyme inhibitor, ramipril, on cardiovascular events in high-risk
patients: the Heart Outcomes Prevention Evaluation (HOPE) Study
Investigators. N Engl J Med. 2000;342:145–153.
15. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus
progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study
(HERS) Research Group. JAMA. 1998;280:605– 613.
16. Krumholz HM, Cohen BJ, Tsevat J, et al. Cost-effectiveness of a
smoking cessation program after myocardial infarction. J Am Coll
Cardiol. 1993;22:1697–1702.

Preventing Heart Attack and Death: 2001 Update

1579

17. Mosca L, Collins P, Herrington DM, et al. Hormone replacement
therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:
499 –503.
18. Timolol-induced reduction in mortality and reinfarction in patents surviving acute myocardial infarction. N Engl J Med. 1981;304:801– 807.
19. O’Keefe JH, Wetzel M, Moe RR, et al. Should an angiotensinconverting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J Am Coll Cardiol. 2001;37:1– 8.
20. Pearson T, Rapaport E, Criqui M, et al. Optimal risk factor management
in the patient after coronary revascularization: a statement for healthcare
professionals from an American Heart Association writing group. Circulation. 1994;90:3125–3133.
21. Randomised trial of cholesterol lowering in 4444 patients with coronary
heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet.
1994;344:1383–1389.
22. Pepine CJ. Aspirin and newer orally active antiplatelet agents in the
treatment of the post-myocardial infarction patient. J Am Coll Cardiol.
1998;32:1126 –1128.
23. Pfeffer MA. ACE inhibition in acute myocardial infarction. N Engl
J Med. 1995;332:118 –120.
24. Pfeffer MA, Braunwald E, Moyé LA, et al, on behalf of the SAVE
Investigators. Effect of captopril on mortality and morbidity in patients
with left ventricular dysfunction after myocardial infarction: results of
the survival and ventricular enlargement trial. N Engl J Med. 1992;327:
669 – 677.
25. Pfeffer MA, Domanski M, Verter J, et al, for the PEACE Investigators.
The continuation of the Prevention of Events with AngiotensinConverting Enzyme inhibition (PEACE) trial. Am Heart J. 2001;142:
375–377.
26. Quinn TG, Alderman EL, McMillan A, et al. Development of new
coronary atherosclerotic lesions during a 4-year multifactor risk
reduction program: the Stanford Coronary Risk Intervention Project
(SCRIP). J Am Coll Cardiol. 1994;24:900 –908.
27. Ryan TJ, Anderson L, Antman EM, et al. ACC/AHA guidelines for the
management of patients with acute myocardial infarction: a report of the
American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee on Management of Acute
Myocardial Infarction). J Am Coll Cardiol. 1996;28:1328 –1428.
28. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine
and clopidogrel. Ann Intern Med. 1998;129:394 – 405.
29. The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern
Med. 1997;157:2413–2446.
30. Smith SC Jr, Blair SN, Criqui MH, et al. Preventing heart attack and
death in patients with coronary disease. Circulation. 1995;92:2– 4.
31. Smith P, Arnesen H, Abdelnoor M. Effects of long-term anticoagulant
therapy in subgroups after acute myocardial infarction. Arch Intern Med.
1992;152:993–997.
32. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and
reinfarction after myocardial infarction. N Engl J Med. 1990;323:
147–152.
33. Viscoli CM, Horwitz RI, Singer BH. Beta-blockers after myocardial
infarction: influence of first-year clinical course on long-term effectiveness. Ann Intern Med. 1993;118:99 –105.
KEY WORDS: AHA Scientific Statements
䡲 atherosclerosis

䡲

prevention

䡲

Downloaded from http://circ.ahajournals.org/ at University of South Carolina--Columbia on June 11, 2013

risk factors

